Showing results (141-150 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
The Lancet. Haematology|June 13, 2018
Venous thromboembolism after induced abortion: a population-based, propensity-score-matched cohort study in CanadaNing Liu, Simone N Vigod, M Michèle Farrugia, et al.
The Lancet. Haematology|February 10, 2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trialDavid A Sallman, Tessa Kerre, Violaine Havelange, et al.
The Lancet. Haematology|August 2, 2016
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trialGary E Raskob, Nick van Es, Annelise Segers, et al.
The Lancet. Haematology|August 27, 2021
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNetAlberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, et al.
The Lancet. Haematology|January 28, 2023
Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease careLydia H Pecker, Eugene Oteng-Ntim, Alecia Nero, et al.
The Lancet. Haematology|December 9, 2025
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trialIsabelle Mahé, Céline Chapelle, Philippe Girard, et al.
The Lancet. Haematology|January 19, 2026
Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in EnglandStephen Kaptoge, Amy McMahon, Yaning Wu, et al.
The Lancet. Haematology|January 17, 2026
Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 studyJonas S Heitmann, Yacine Maringer, Susanne Jung, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignanciesPaul J Bröckelmann, Edward R Scheffer Cliff, Gloria Iacoboni, et al.
Pageof 73